Expert Insights

Lyudmila Bazhenova, MD, discusses updated results from the TRUST-I and TRUST-II trials assessing taletrectinib in TKI-naive patients with ROS1-positive non-small cell lung cancer.

Francesca Jackson-Spence, MBChB, discusses final results from the phase 2 CALYPSO study evaluating savolitinib plus durvalumab in metastatic papillary renal cell carcinoma.

Jacqueline Barrientos, MD, discusses emerging combination treatment strategies in chronic lymphocytic leukemia.

Alison Schram, MD, discusses results from the phase 2 PYNNACLE trial which assessed rezatapopt in TP53 Y220C mutated advanced or metastatic ovarian cancer.

Jonathan Friedberg, MD, MMSc, discusses results from the SWOG S1826 trial which led to the recent FDA approval of nivolumab plus doxorubicin, vinblastine, and dacarbazine for patients with advanced-stage Hodgkin lymphoma.

Brian Slomovitz, MD, discusses results from the ROSELA trial which led to the recent FDA approval of relacorilant plus nab-paclitaxel for patients with platinum-resistant ovarian cancer.

Catherine Haring, MD, discusses findings from a study evaluating ctDNA as a biomarker in patients with HPV-related oropharyngeal cancer undergoing surgery.

Robert Jenq, MD, discusses how microbiome factors and emerging interventions may influence and improve CAR T-cell therapy outcomes.

Neil Kay, MD, discusses the evolving debate between continuous versus fixed-duration therapy for patients with chronic lymphocytic leukemia.

Emese Zsiros, MD, PhD, discusses results from the phase 3 KEYNOTE-B96 trial, which demonstrated that pembrolizumab improves survival while maintaining quality of life in patients with platinum-resistant ovarian cancer.